HRP20150440T1 - Metode za lijeäśenje endometrioze - Google Patents
Metode za lijeäśenje endometrioze Download PDFInfo
- Publication number
- HRP20150440T1 HRP20150440T1 HRP20150440TT HRP20150440T HRP20150440T1 HR P20150440 T1 HRP20150440 T1 HR P20150440T1 HR P20150440T T HRP20150440T T HR P20150440TT HR P20150440 T HRP20150440 T HR P20150440T HR P20150440 T1 HRP20150440 T1 HR P20150440T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- progestogen
- medicine
- progesterone
- administration
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title claims 6
- 239000003814 drug Substances 0.000 claims 19
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 18
- 239000000583 progesterone congener Substances 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 13
- 229960003387 progesterone Drugs 0.000 claims 9
- 239000000186 progesterone Substances 0.000 claims 9
- 230000003902 lesion Effects 0.000 claims 5
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229960004976 desogestrel Drugs 0.000 claims 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims 2
- 229960002941 etonogestrel Drugs 0.000 claims 2
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims 2
- 229960005352 gestodene Drugs 0.000 claims 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims 2
- -1 levonogestrel Chemical compound 0.000 claims 2
- 229960004400 levonorgestrel Drugs 0.000 claims 2
- 210000003041 ligament Anatomy 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 229960004616 medroxyprogesterone Drugs 0.000 claims 2
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 claims 2
- 229940053934 norethindrone Drugs 0.000 claims 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 2
- 229960000417 norgestimate Drugs 0.000 claims 2
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 238000012800 visualization Methods 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000005641 Adenomyosis Diseases 0.000 claims 1
- 208000002938 adenomyoma Diseases 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 201000009274 endometriosis of uterus Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002350 laparotomy Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Surgical Instruments (AREA)
Claims (24)
1. Lijek za uporabu u postupku liječenja endometrioze intralezijskom primjenom, lijek sadrži:
suspenziju koja nije na bazi ulja koja sadrži progestogen; pri čemu je lijek oblikovan za intralezijsko unošenje; i
pri čemu je količina progestogena primjenjena po jednoj dozi na leziju ekvivalentna aktivnosti od 0.2 – 5 g progesterona.
2. Lijek za uporabu sukladno Zahtjevu 1, pri čemu je lijek oblikovan za povećano zadržavanje na mjestu uboda.
3. Lijek za uporabu sukladno Zahtjevu 1 ili 2, pri čemu je progestogen odabran iz progesterona, dezogestrela, etonogestrela, gestodena, levonogestrela, medroksiprogesterona, noretisterona, norgestimata i norgestrela.
4. Lijek za uporabu sukladno bilo kojem od Zahtjeva 1 do 3, pri čemu je navedeni progestogen progesteron.
5. Lijek za uporabu sukladno Zahtjevu 4, pri čemu je količina progestogena primjenjena po jednoj dozi na leziju ekvivalentna aktivnosti od 1 – 2 g progesterona.
6. LIjek za uporabu sukladno bilo kojem od Zahtjeva 1 do 5, pri čemu je progestogen mikroniziran.
7. Lijek za uporabu sukladno Zahtjevu 6, pri čemu je progestogen mikroniziran do stupnja finoće veće od 10 mm.
8. Lijek za uporabu sukladno Zahtjevu 6 ili 7, pri čemu je progestogen mikroniziran do stupnja finoće manje ili jednake 100 mm.
9. Lijek za uporabu sukladno bilo kojem od Zahtjeva 1 do 8, pri čemu je koncentracija progestogena 1 -50 % težine/volumena lijeka.
10. Lijek za uporabu sukladno bilo kojem od ranijih Zahtjeva, pri čemu je navedeni progestogen jedini aktivni sastojak.
11. Lijek za uporabu sukladno bilo kojem od ranijih Zahtjeva, pri čemu je lijek oblikovan za izravnu primjenu u pojedinačnim dozama.
12. Lijek za uporabu sukladno bilo kojem od ranijih Zahtjeva, pri čemu je lijek oblikovan za razrjeđivanje u nosaču prije primjene.
13. Uporaba progestogena za proizvodnju lijeka za uporabu u liječenju endometrioze intralezijskom primjenom, lijek sadrži:
suspenziju koja nije na bazi ulja koja sadrži progestogen;
i
pri čemu je količina progestogena primjenjena po jednoj dozi na leziju ekvivalentna aktivnosti od 0.2 – 5 g progesterona.
14. Uporaba sukladno Zahtjevu 13, pri čemu je progestogen odabran iz progesterona, dezogestrela, etonogestrela, gestodena, levonogestrela, medroksiprogesterona, noretisterona, norgestimata, i norgestrela.
15. Uporaba sukladno Zahtjevu 13 ili 14, pri čemu je navedeni progestogen progesteron.
16. Uporaba sukladno Zahtjevu 15, pri čemu je količina progesterona primjenjena po jednoj dozi na leziju ekvivalentna aktivnosti od 1 – 2 g progesterona.
17. Uporaba sukladno bilo kojem od Zahtjeva 13 do 16, pri čemu je progestogen jedini aktivni sastojak u navedenom lijeku.
18. Uporaba sukladno bilo kojem od Zahtjeva 13 do 17, pri čemu je progestogen mikroniziran.
19. Uporaba sukladno bilo kojem od Zahtjeva 13 do 18, pri čemu je intralezijska primjena transvaginalna ili intravaginalna.
20. Uporaba sukladno bilo kojem od Zahtjeva 13 do 19, pri čemu je intralezijska primjena endoskopska ili putem otvorene kirurške primjene.
21. Uporaba sukladno bilo kojem od Zahtjeva 13 do 20, pri čemu je intralezijska primjena putem laparotomije.
22. Uporaba sukladno bilo kojem od Zahtjeva 13 do 21, pri čemu je navedena endometrioza eksterna endometrioza, endometrioma, adenomioza, adenomioma, adenomiotski noduli uterosakralnih ligamenata ili endometriotski noduli različiti od uterosakralnih ligamenata ili kombinacije istih.
23. Uporaba sukladno bilo kojem od Zahtjeva 13 do 22, pri čemu se sadržaj lezije aspirira.
24. Uporaba sukladno bilo kojem od Zahtjeva 13 do 23, pri čemu je primjena vođena izravnom vizualizacijom ili vizualizacijom uz pomoć ultrazvuka.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50021703P | 2003-09-03 | 2003-09-03 | |
| US52635503P | 2003-12-01 | 2003-12-01 | |
| EP04769463.3A EP1660009B1 (en) | 2003-09-03 | 2004-08-27 | Methods for the treatment of endometriosis |
| PCT/IB2004/003103 WO2005020880A2 (en) | 2003-09-03 | 2004-08-27 | Methods for the treatment of endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150440T1 true HRP20150440T1 (hr) | 2015-07-03 |
Family
ID=34278698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150440TT HRP20150440T1 (hr) | 2003-09-03 | 2015-04-22 | Metode za lijeäśenje endometrioze |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9532995B2 (hr) |
| EP (2) | EP2617411A1 (hr) |
| JP (2) | JP5651279B2 (hr) |
| KR (2) | KR101285137B1 (hr) |
| CN (1) | CN101849906A (hr) |
| AU (1) | AU2004267956B2 (hr) |
| BR (1) | BRPI0413200A (hr) |
| CA (1) | CA2537702C (hr) |
| DK (1) | DK1660009T3 (hr) |
| EA (1) | EA015356B1 (hr) |
| ES (1) | ES2535430T3 (hr) |
| HK (1) | HK1095529A1 (hr) |
| HR (1) | HRP20150440T1 (hr) |
| HU (1) | HUE025239T2 (hr) |
| IL (1) | IL174014A0 (hr) |
| MA (1) | MA28083A1 (hr) |
| NO (1) | NO20061502L (hr) |
| PL (1) | PL1660009T3 (hr) |
| PT (1) | PT1660009E (hr) |
| SI (1) | SI1660009T1 (hr) |
| TN (1) | TNSN06070A1 (hr) |
| WO (1) | WO2005020880A2 (hr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080306034A1 (en) * | 2007-06-11 | 2008-12-11 | Juneau Biosciences, Llc | Method of Administering a Therapeutic |
| WO2009140126A1 (en) * | 2008-05-14 | 2009-11-19 | Juneau Biosciences, Llc | Method of administering a therapeutic |
| WO2010124101A2 (en) | 2009-04-22 | 2010-10-28 | Juneau Biosciences, Llc | Genetic markers associated with endometriosis and use thereof |
| EP2471537A1 (en) * | 2010-12-30 | 2012-07-04 | PregLem S.A. | Treatment of pain associated with dislocation of basal endometrium |
| AR082266A1 (es) * | 2011-05-13 | 2012-11-28 | Univ Nac Del Litoral | Microparticula inyectable de liberacion controlada |
| PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2015073066A1 (en) * | 2013-11-12 | 2015-05-21 | University Of Utah Research Foundation | Glycol chitin based thermosensitive hydrogel for vaginal delivery of progesterone |
| CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| CA3038897A1 (en) * | 2016-09-28 | 2018-04-05 | Atossa Genetics Inc. | Methods of adoptive cell therapy |
| RU2661701C1 (ru) * | 2017-02-09 | 2018-07-19 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Способ лапароскопического лечения узловых форм аденомиоза |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| WO2021173373A1 (en) * | 2020-02-26 | 2021-09-02 | Fordoz Pharma Corp. | Injectable controlled-release formulations of progestogen drugs |
| RU2746476C1 (ru) * | 2020-04-28 | 2021-04-14 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Способ хирургического лечения глубокого инфильтративного эндометриоза ректовагинальной перегородки |
| GB2594726A (en) * | 2020-05-05 | 2021-11-10 | Nadezhda Reproductive Science Ood | Adenomyosis associated infertility and HDACIs |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US61303A (en) * | 1867-01-15 | James yocom | ||
| US150A (en) | 1837-03-25 | Island | ||
| US5362A (en) | 1847-11-06 | Ice-ctjttee | ||
| US389A (en) | 1837-09-21 | Mode of supporting the bodies of railroad-cars and carriages | ||
| US12703A (en) * | 1855-04-10 | Gabhst-chaie | ||
| US720A (en) | 1838-04-28 | Improved mode of forming a kiln for making charcoal | ||
| US4038A (en) | 1845-05-10 | Boot-crimp | ||
| US5543A (en) | 1848-05-02 | of jbesey city | ||
| US3089815A (en) * | 1951-10-11 | 1963-05-14 | Lieb Hans | Injectable pharmaceutical preparation, and a method of making same |
| GB784659A (en) | 1954-11-26 | 1957-10-16 | Upjohn Co | Therapeutic compositions and aqueous suspensions thereof |
| US4038389A (en) * | 1975-05-07 | 1977-07-26 | The Upjohn Company | Medroxyprogesterone acetate compositions |
| FR2663223B1 (fr) | 1990-06-14 | 1994-12-02 | Af Aplicaciones Far Lab | Forme galenique parenterale. |
| GB2252497B (en) | 1991-02-04 | 1995-01-18 | Elsimar Metzker Coutinho | Pharmaceutical composition |
| JPH0735335B2 (ja) | 1991-02-28 | 1995-04-19 | 五十嵐 正雄 | 子宮内膜症の治療薬 |
| ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
| HU222501B1 (hu) | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| RU2073534C1 (ru) | 1993-06-04 | 1997-02-20 | Сочинский научно-исследовательский институт курортологии и физиотерапии МЗ РФ | Способ лечения генитального эндометриоза |
| US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| EP0792152B1 (en) * | 1994-11-22 | 2004-04-14 | Balance Pharmaceuticals, Inc. | Methods of contraception |
| EP0785212A1 (en) | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New 19-nor-pregnene derivatives |
| US6416778B1 (en) * | 1997-01-24 | 2002-07-09 | Femmepharma | Pharmaceutical preparations and methods for their regional administration |
| US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
| US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| WO2000015766A1 (en) | 1998-09-16 | 2000-03-23 | Oncopharmaceutical, Inc. | Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| CA2311937A1 (en) * | 1998-10-09 | 2000-04-20 | Pharmacia & Upjohn Company Llc | Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis |
| JP2001051773A (ja) * | 1999-08-16 | 2001-02-23 | Toshiaki Matsuhashi | キーボードカバー |
| US6613355B2 (en) * | 2000-05-11 | 2003-09-02 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
| JP2003533464A (ja) * | 2000-05-15 | 2003-11-11 | フアルマシア・イタリア・エツセ・ピー・アー | 安定化ステロイド懸濁液 |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| WO2002028387A1 (en) | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| JP4724354B2 (ja) | 2001-02-23 | 2011-07-13 | ジェネンテック， インコーポレイテッド | 注射用の崩壊性ポリマー |
| JP4273208B2 (ja) * | 2001-03-30 | 2009-06-03 | チッソ株式会社 | 婦人科疾患治療剤 |
| US20040105889A1 (en) | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
-
2004
- 2004-08-27 KR KR1020067004304A patent/KR101285137B1/ko active IP Right Grant
- 2004-08-27 PT PT47694633T patent/PT1660009E/pt unknown
- 2004-08-27 AU AU2004267956A patent/AU2004267956B2/en active Active
- 2004-08-27 BR BRPI0413200-9A patent/BRPI0413200A/pt not_active Application Discontinuation
- 2004-08-27 CA CA2537702A patent/CA2537702C/en active Active
- 2004-08-27 CN CN201010193233A patent/CN101849906A/zh active Pending
- 2004-08-27 WO PCT/IB2004/003103 patent/WO2005020880A2/en active Application Filing
- 2004-08-27 EP EP13164182.1A patent/EP2617411A1/en not_active Withdrawn
- 2004-08-27 HU HUE04769463A patent/HUE025239T2/en unknown
- 2004-08-27 SI SI200432237T patent/SI1660009T1/sl unknown
- 2004-08-27 ES ES04769463.3T patent/ES2535430T3/es active Active
- 2004-08-27 JP JP2006525216A patent/JP5651279B2/ja active Active
- 2004-08-27 EA EA200600524A patent/EA015356B1/ru not_active IP Right Cessation
- 2004-08-27 EP EP04769463.3A patent/EP1660009B1/en active Active
- 2004-08-27 DK DK04769463.3T patent/DK1660009T3/en active
- 2004-08-27 KR KR1020117031425A patent/KR101288265B1/ko active IP Right Grant
- 2004-08-27 US US10/927,822 patent/US9532995B2/en active Active
- 2004-08-27 PL PL04769463T patent/PL1660009T3/pl unknown
-
2006
- 2006-02-28 IL IL174014A patent/IL174014A0/en unknown
- 2006-03-01 TN TNP2006000070A patent/TNSN06070A1/en unknown
- 2006-04-03 MA MA28910A patent/MA28083A1/fr unknown
- 2006-04-03 NO NO20061502A patent/NO20061502L/no not_active Application Discontinuation
-
2007
- 2007-03-12 HK HK07102652.8A patent/HK1095529A1/xx unknown
-
2012
- 2012-10-05 JP JP2012222814A patent/JP2013035866A/ja active Pending
-
2014
- 2014-10-27 US US14/524,639 patent/US9468647B2/en active Active
-
2015
- 2015-04-22 HR HRP20150440TT patent/HRP20150440T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150440T1 (hr) | Metode za lijeäśenje endometrioze | |
| JP2007509032A5 (hr) | ||
| ES2337129T3 (es) | Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal. | |
| KR20220144885A (ko) | 월경통 및 생리통의 관리방법 | |
| CN103313715A (zh) | 基底子宫内膜异位相关疼痛的治疗 | |
| PT646008E (pt) | Minimizacao de hemorragias secundarias associadas a progestina | |
| ES2296943T3 (es) | Sistema de administracion de un medicamento estrogeno tetrahidroxilado destinado a la contracepcion hormonal. | |
| Gomes et al. | The levonorgestrel-releasing intrauterine system and endometriosis staging | |
| MX2014000474A (es) | Tratamiento de la menorragia asociada con fibromas uterinos. | |
| Afolabi et al. | Comparing perioperative vaginal misoprostol with intraoperative pericervical hemostatic tourniquet in reducing blood loss during abdominal myomectomy: A randomized controlled trial | |
| DE202011110360U1 (de) | Artikel für die weibliche Hygiene mit antifibrinolytischem oder hämostatischem Wirkstoff und pharmazeutische Zusammensetzung | |
| Batur et al. | Update on contraception: benefits and risks of the new formulations | |
| JP2009539759A (ja) | 経口１相性低用量避妊薬に対する新しい投与計画 | |
| Holland-Hall | Heavy menstrual bleeding in adolescents: Normal variant or a bleeding disorder? | |
| Holland-Hall | HEAVY MENSTRUAL BLEEDING IN ADOLESCENTS NORMAL VARIANT OR A BLEEDING DISORDER? | |
| Mansour | Use of the new progestogens in contraception and gynaecology | |
| US20190262361A1 (en) | Progesterone Receptor Modulators for Use in the Therapy of Uterine Fibroids | |
| ES2316402T3 (es) | Mesoprogestagenos (moduladores de los receptores de progesterona) como un componente de composiciones para la hormonoterapia restitutiva (hrt). | |
| AU771059B2 (en) | Use of antiprogestagens in combined therapy | |
| Kost et al. | Tranexamic acid (Lysteda) for cyclic heavy menstrual bleeding | |
| Stockburger et al. | Menstrual Health | |
| US20140030313A1 (en) | Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non-steroidal anti-inflammatory drug | |
| Vliet | M. an.(2010, Ma 19) | |
| ZA200106689B (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding. | |
| JP2001089371A (ja) | ニトロイミダゾール系化合物を含むアトピー性皮膚炎治療用の外用剤 |